VÃ-ctor JimÃ©nez-Yuste

List of Publications by Year
in descending order

243 papers	6,689 citations	76326 40 h-index	88630 70 g-index
261 all docs	261 docs citations	261 times ranked	4528 citing authors

#	Article	IF	Citations
1	Hemophilia treatment in 2021: Choosing theâ€•optimalâ€•treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Reviews, 2022, 52, 100890.	5.7	22
2	Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. Archivos De Bronconeumologia, 2022, 58, 117-124.	0.8	20
3	Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis. Haemophilia, 2022, 28, 138-144.	2.1	11
4	Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. Thrombosis and Haemostasis, 2022, 122, 295-299.	3.4	40
5	Efficacy and safety evaluation of Fanhdi^{Â®}, a plasmaâ€derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study. Haemophilia, 2022, 28, .	2.1	1
6	Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response. Thrombosis and Haemostasis, 2022, 122, 913-925.	3.4	1
7	Total knee arthroplasty in hemophilia: lessons learned and projections of whatâ€™s next for hemophilic knee joint health. Expert Review of Hematology, 2022, 15, 65-82.	2.2	5
8	Clinical Efficacy and Safety of FanhdiÂ®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210743.	1.7	1
9	Arthropathy in people with mild haemophilia: Exploring risk factors. Thrombosis Research, 2022, 211, 19-26.	1.7	9
10	International consensus recommendations on the management of people with haemophilia B. Therapeutic Advances in Hematology, 2022, 13, 204062072210852.	2.5	13
11	Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Advances, 2022, 6, 3422-3432.	5.2	22
12	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia, 2022, 28, .	2.1	10
13	Immune tolerance induction in the era of emicizumab â€“ still the first choice for patients with haemophilia A and inhibitors?. Haemophilia, 2022, 28, 215-222.	2.1	7
14	Acquired Haemophilia A: A 15-Year Single-Centre Experience of Demography, Clinical Features and Outcome. Journal of Clinical Medicine, 2022, 11, 2721.	2.4	3
15	Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study. TH Open, 2022, 06, e124-e134.	1.4	3
16	Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model. Haematologica, 2021, 106, 1902-1909.	3.5	8
17	COVIDâ€19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery. Haemophilia, 2021, 27, e137-e139.	2.1	11
18	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood, 2021, 137, 2231-2242.	1.4	133

#	Article	IF	Citations
19	Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid. Expert Review of Hematology, 2021, 14, 1-5.	2.2	5
20	Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Review of Hematology, 2021, 14, 143-148.	2.2	16
21	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEADâ€US system. Haemophilia, 2021, 27, 479-487.	2.1	8
22	Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak. Leukemia and Lymphoma, 2021, 62, 2034-2036.	1.3	0
23	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121, 1400-1408.	3.4	14
24	Healthâ€related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitorsâ€"A nonâ€interventional study. Haemophilia, 2021, 27, 398-407.	2.1	15
25	Practical considerations for nonfactorâ€replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia, 2021, 27, 340-350.	2.1	15
26	Principles of care for acquired hemophilia. European Journal of Haematology, 2021, 106, 762-773.	2.2	11
27	Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia. Medicina (Lithuania), 2021, 57, 219.	2.0	1
28	The Importance of Platelet Glycoside Residues in the Haemostasis of Patients with Immune Thrombocytopaenia. Journal of Clinical Medicine, 2021, 10, 1661.	2.4	8
29	Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia. Expert Review of Hematology, 2021, 14, 429-436.	2.2	7
30	Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia, 2021, 27, 519-530.	2.1	20
31	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865.	2.1	21
32	Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors. Hamostaseologie, 2021, 41, .	1.9	3
33	Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. Expert Opinion on Biological Therapy, 2021, 21, 1165-1171.	3.1	3
34	PLATELET TRANSFUSION REFRACTORINESS (PTR) IN A TERTIARY REFERRAL HOSPITAL. Transfusion and Apheresis Science, 2021, 60, 103143.	1.0	0
35	Postâ€hoc analysis on the longâ€term response to fixedâ€dose prophylaxis with N8â€GP in patients with haemophilia A. Haemophilia, 2021, , .	2.1	0
36	Type 2N VWD: Conclusions from the Spanish PCMâ€EVWâ€ES project. Haemophilia, 2021, 27, 1007-1021.	2.1	0

#	Article	IF	Citations
37	Delivery of AAVâ€based gene therapy through haemophilia centresâ€"A need for reâ€evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia, 2021, 27, 967-973.	2.1	29
38	Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, e772-e775.	2.1	8
39	Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis. Blood, 2021, 138, 344-344.	1.4	6
40	Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials. Blood, 2021, 138, 345-345.	1.4	4
41	Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia. Blood, 2021, 138, 1021-1021.	1.4	0
42	Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests. Blood, 2021, 138, 4235-4235.	1.4	0
43	Emicizumab Prophylaxis in Persons with Hemophilia A, Aged â‰¥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY). Blood, 2021, 138, 2103-2103.	1.4	0
44	Ex Vivo Evaluation of the Effect of Plasma-Derived Factor VIII/Von Willebrand Factor in Patients with Severe Hemophilia_A on Prophylaxis with Emicizumab By Thrombin Generation Assay. Blood, 2021, 138, 4233-4233.	1.4	0
45	Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia. Blood, 2021, 138, 3158-3158.	1.4	1
46	Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study. Blood, 2021, 138, 343-343.	1.4	7
47	Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency. Blood, 2021, 138, 1046-1046.	1.4	0
48	Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A. Thrombosis and Haemostasis, 2020, 120, 277-288.	3.4	8
49	Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Haemophilia, 2020, 26, 64-72.	2.1	17
50	Insights into the Procoagulant Profile of Patients with Systemic Lupus Erythematosus without Antiphospholipid Antibodies. Journal of Clinical Medicine, 2020, 9, 3297.	2.4	8
51	Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. Journal of Hematology and Oncology, 2020, 13, 133.	17.0	171
52	Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. Frontiers in Medicine, 2020, 7, 576558.	2.6	7
53	Managing the frontâ€line treatment for diffuse large B cell lymphoma and highâ€grade B cell lymphoma during the COVIDâ€19 outbreak. British Journal of Haematology, 2020, 191, 386-389.	2.5	13
54	Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatric Blood and Cancer, 2020, 67, e28474.	1.5	11

#	Article	IF	Citations
55	Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia, 2020, 26, 800-808.	2.1	2
56	What COVID-19 can mean for people with hemophilia beyond the infection risk. Expert Review of Hematology, 2020, 13, 1073-1079.	2.2	7
57	European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases, 2020, 15, 219.	2.7	6
58	No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19. Transfusion and Apheresis Science, 2020, 59, 102921.	1.0	18
59	HJHS 2.1 and HEAD-US assessment in the hemophilic joints: How do their findings compare?. Blood Coagulation and Fibrinolysis, 2020, 31, 387-392.	1.0	14
60	Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary. Haemophilia, 2020, 26, 999-1008.	2.1	7
61	Clinical trials and Haemophilia during the COVIDâ€19 pandemic: Madrid's experience. Haemophilia, 2020, 26, e247-e249.	2.1	5
62	Intraâ€articular injections in people with haemophilia in the COVIDâ€19 era. Haemophilia, 2020, 26, e250-e252.	2.1	4
63	International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 2020, 105, 1791-1801.	3.5	182
64	Thromboprophylaxis in a patient with COVIDâ€19 and severe hemophilia A on emicizumab prophylaxis. Journal of Thrombosis and Haemostasis, 2020, 18, 2202-2204.	3.8	15
65	Registry of patients with congenital bleeding disorders and COVIDâ€19 in Madrid. Haemophilia, 2020, 26, 773-778.	2.1	18
66	Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort. Thrombosis and Haemostasis, 2020, 120, 437-448.	3.4	2
67	Platelet and immune characteristics of immune thrombocytopaenia patients nonâ€responsive to therapy reveal severe immune dysregulation. British Journal of Haematology, 2020, 189, 943-953.	2.5	27
68	Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood, 2020, 136, 3-5.	1.4	3
69	â€˜Do not Doâ€™ Recommendations in Hemophilia. Cardiovascular & Hematological Disorders Drug Targets, 2020, 20, 168-174.	0.7	3
70	Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group. Blood, 2020, 136, 12-13.	1.4	4
71	Thrombin Generation Related to Netosis in Patients with Systemic Lupus Erythematosus. Blood, 2020, 136, 10-11.	1.4	1
72	Thein Vitroprocoagulant Effects of Standard and Extended Half-Life Recombinant Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. Blood, 2020, 136, 18-19.	1.4	0

#	Article	IF	Citations
73	Fibrin Polymerization Ability Influences Joint Condition in Patients with Severe Haemophilia. Blood, 2020, 136, 17-18.	1.4	0
74	Study of the Effect of Fibrinogen, Factor XIII and Recombinant Activated Factor VII in a Model of Trauma-Induced Coagulopathy. Blood, 2020, 136, 6-7.	1.4	0
75	Glycoside Residues on Platelet's Surface Regulate Platelet Function, Apoptosis and Binding of Coagulation Complexes in Patients with Immune Thrombocytopaenia. Blood, 2020, 136, 10-11.	1.4	0
76	Common themes and challenges in hemophilia care: a multinational perspective. Hematology, 2019, 24, 39-48.	1.5	17
77	Fixed doses of N8â€GP prophylaxis maintain moderateâ€toâ€mild factor VIII levels in the majority of patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 542-554.	2.3	17
78	Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. Haemophilia, 2019, 25, 969-978.	2.1	24
79	Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood, 2019, 134, 1973-1982.	1.4	103
80	Hindfoot malalignment in adults with haemophilic ankle arthropathy: The importance of early detection and orthotic treatment. Haemophilia, 2019, 25, 500-508.	2.1	8
81	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematology,the, 2019, 6, e295-e305.	4.6	252
82	Rapid and sustained immune tolerance to inhibitors induced by a plasmaâ€derived, VWFâ€containing FVIII concentrate. Haemophilia, 2019, 25, e110-e113.	2.1	5
83	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. Thrombosis and Haemostasis, 2019, 119, 645-659.	3.4	31
84	Inhibitors: A Need for Eradication?. Acta Haematologica, 2019, 141, 151-155.	1.4	15
85	Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study. BMJ Open, 2019, 9, e028012.	1.9	7
86	A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood, 2019, 134, 2127-2138.	1.4	241
87	Haemophilia: Reasons for visits to the paediatric emergency department. Anales De PediatrÃa (English) Tj ETQq1 1 0.784314 rgBT /Ov	0.2	1
88	Accelerating recovery from acute hemarthrosis in patients with hemophilia. Blood Coagulation and Fibrinolysis, 2019, 30, 111-119.	1.0	26
89	Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A. European Journal of Pharmaceutical Sciences, 2019, 128, 215-221.	4.0	1
90	Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. Haemophilia, 2019, 25, 60-66.	2.1	32

#	Article	IF	Citations
91	Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficultâ€¢toâ€¢treat patients. European Journal of Haematology, 2019, 102, 111-122.	2.2	78
92	Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEADâ€US) score. Haemophilia, 2019, 25, 144-153.	2.1	11
93	Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA. Haematologica, 2019, 104, 587-598.	3.5	13
94	Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein. Blood, 2019, 134, 4929-4929.	1.4	2
95	Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus. Blood, 2019, 134, 1141-1141.	1.4	1
96	Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study. Hamostaseologie, 2019, 39, .	1.9	1
97	Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study. Hamostaseologie, 2019, 39, .	1.9	0
98	Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments. Blood, 2019, 134, 1089-1089.	1.4	1
99	Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. Blood, 2019, 134, 1118-1118.	1.4	0
100	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfusion, 2019, 17, 391-398.	0.4	18
101	The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia. Expert Review of Hematology, 2018, 11, 253-261.	2.2	49
102	European principles of inhibitor management in patients with haemophilia. Orphanet Journal of Rare Diseases, 2018, 13, 66.	2.7	33
103	Factors Involved in Maintaining Haemostasis in Patients with Myelodysplastic Syndrome. Thrombosis and Haemostasis, 2018, 47, 734-744.	3.4	1
104	Point-of-care Ultrasonography in Orthopedic Management of Hemophilia: Multiple Uses of an Effective Tool. HSS Journal, 2018, 14, 307-313.	1.7	15
105	Immune thrombocytopenia â€“ in defence of the platelet count. Response to Hill. British Journal of Haematology, 2018, 182, 130-131.	2.5	0
106	Haemophilia B: Where are we now and what does the future hold?. Blood Reviews, 2018, 32, 52-60.	5.7	41
107	Practical aspects of extended half-life products for the treatment of haemophilia. Therapeutic Advances in Hematology, 2018, 9, 295-308.	2.5	85
108	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. New England Journal of Medicine, 2018, 379, 811-822.	27.0	489

#	Article	IF	Citations
109	VarÃ³n de 60 aÃ±os de edad con enfermedad pulmonar obstructiva crÃ³nica y eosinofilia. Archivos De Bronconeumologia, 2018, 54, 394-395.	0.8	1
110	Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia, 2018, 24, 693-702.	2.1	60
111	A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. Journal of Thrombosis and Haemostasis, 2018, 16, 2184-2195.	3.8	56
112	Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. PLoS ONE, 2018, 13, e0197876.	2.5	6
113	Head trauma in the haemophilic child and management in a paediatric emergency department: Descriptive study. Haemophilia, 2018, 24, e187-e193.	2.1	4
114	A 60-Year-Old Male Smoker With Chronic Obstructive Pulmonary Disease and Hypereosinophilia. Archivos De Bronconeumologia, 2018, 54, 394-395.	0.8	1
115	Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT^{Â®} in patients with severe haemophilia A without inhibitors. Haemophilia, 2017, 23, e50-e54.	2.1	35
116	Outcome measures for adult and pediatric hemophilia patients with inhibitors. European Journal of Haematology, 2017, 99, 103-111.	2.2	8
117	New findings on inhibitor development: from registries to clinical studies. Haemophilia, 2017, 23, 4-13.	2.1	24
118	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica, 2017, 102, 2005-2014.	3.5	35
119	The pharmacokinetics and pharmacodynamics of singleâ€dose and multipleâ€dose recombinant activated factor VII in patients with haemophilia A or B. Haemophilia, 2017, 23, 868-876.	2.1	14
120	Outcome measures in European patients with haemophilia. Haemophilia, 2017, 23, 222-229.	2.1	8
121	Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. Thrombosis and Haemostasis, 2017, 117, 66-74.	3.4	36
122	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thrombosis and Haemostasis, 2017, 117, 252-261.	3.4	96
123	Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood, 2017, 130, 89-89.	1.4	41
124	Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. Blood Transfusion, 2017, 15, 77-84.	0.4	6
125	Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thrombosis and Haemostasis, 2016, 115, 872-895.	3.4	31
126	Longâ€term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasmaâ€derived FVIII/VWF product: the longâ€term ITI study. Haemophilia, 2016, 22, 859-865.	2.1	19

#	Article	IF	Citations
127	Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. Aids, 2016, 30, 1141-1142.	2.2	7
128	Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors. Haemophilia, 2016, 22, e71-e74.	2.1	7
129	Pain and pain management in haemophilia. Blood Coagulation and Fibrinolysis, 2016, 27, 845-854.	1.0	66
130	Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. European Journal of Haematology, 2016, 96, 461-474.	2.2	15
131	First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia, 2016, 22, 87-95.	2.1	47
132	Procoagulant profile in patients with immune thrombocytopenia. British Journal of Haematology, 2016, 175, 925-934.	2.5	42
133	Current view and outcome of ITI therapy - A change over time?. Thrombosis Research, 2016, 148, 38-44.	1.7	18
134	Molecular and clinical profile of von Willebrand disease in Spain (PCMâ€“EVWâ€“ES): Proposal for a new diagnostic paradigm. Thrombosis and Haemostasis, 2016, 115, 40-50.	3.4	36
135	The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders. Thrombosis and Haemostasis, 2016, 116, S1.	3.4	3
136	The burden of inhibitors in haemophilia patients. Thrombosis and Haemostasis, 2016, 116, S10-S17.	3.4	52
137	Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Research, 2016, 213, 224-229.	2.2	23
138	Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies. European Journal of Haematology, 2015, 95, 1-15.	2.2	4
139	Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thrombosis and Haemostasis, 2015, 114, 676-684.	3.4	9
140	Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thrombosis and Haemostasis, 2015, 114, 46-55.	3.4	33
141	Inhibitor development and mortality in nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2015, 13, 1217-1225.	3.8	65
142	Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia, 2015, 21, 458-464.	2.1	51
143	Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respiratory Medicine,the, 2015, 3, 554-562.	10.7	113
144	Arthroscopic debridement for ankle haemophilic arthropathy. Blood Coagulation and Fibrinolysis, 2015, 26, 279-281.	1.0	11

#	Article	IF	Citations
145	The pharmacokinetics of a Bâ€domain truncated recombinant factorÂVIII, turoctocog alfa (NovoEightÂ®), in patients with hemophiliaÂA. Journal of Thrombosis and Haemostasis, 2015, 13, 370-379.	3.8	25
146	Lightâ€chain amyloidosis presenting as a change in bleeding phenotype in a patient with mild haemophilia A. Haemophilia, 2015, 21, e92-4.	2.1	0
147	Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in BehÃ§et Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 621-628.	2.7	29
148	Switching treatments in haemophilia: is there a risk of inhibitor development?. European Journal of Haematology, 2015, 94, 284-289.	2.2	21
149	Hematological Concepts and Hematological Perioperative Treatment. , 2015, , 13-19.		0
150	The Analgesic Efficacy of a COX-2 Inhibitor (Oral Celecoxib) in Adult Hemophilic Patients and Intense Joint Pain Secondary to Advanced Hemophilic Arthropathy. , 2015, , 101-104.		0
151	Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study. Blood, 2015, 126, 2282-2282.	1.4	1
152	ValoraciÃ³n de la eficacia percibida de la dinamica grupal â€œÂ¿quÃ©-tal?â€•Para el autocuidado y aprendizaje mutuo en un equipo asistencial. Psicooncologia, 2014, 10, .	0.3	2
153	Effect of thrombopoietinâ€receptor agonists on a proliferationâ€inducing ligand (<scp>APRIL</scp>) plasma levels in patients with immune thrombocytopaenia. British Journal of Clinical Pharmacology, 2014, 78, 674-676.	2.4	4
154	Severe postoperative haemarthrosis following a total knee replacement in a haemophiliac patient caused by a pseudoaneurysm: early treatment with arterial embolization. Haemophilia, 2014, 20, e86-9.	2.1	12
155	Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF â€containing plasmaâ€derived FVIII concentrate. Haemophilia, 2014, 20, 83-91.	2.1	56
156	Efficacy of celecoxib in the treatment of joint pain caused by advanced haemophilic arthropathy in adult patients with haemophilia <scp>A</scp>. Haemophilia, 2014, 20, e225-7.	2.1	17
157	Radiosynovectomy in haemophilia: Long-term results of 500 procedures performed in a 38-year period. Thrombosis Research, 2014, 134, 985-990.	1.7	70
158	Is radiosynovectomy (RS) effective for joints damaged by haemophilia with articular degeneration in simple radiography (ADSR)?. Thrombosis Research, 2014, 133, 875-879.	1.7	13
159	Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?. Thrombosis Research, 2014, 133, 967-971.	1.7	10
160	Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single <scp>FVIII</scp>/<scp>VWF</scp> product. Haemophilia, 2014, 20, e414-7.	2.1	15
161	Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thrombosis and Haemostasis, 2014, 112, 65-72.	3.4	28
162	Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfusion, 2014, 12, 314-9.	0.4	46

#	Article	IF	Citations
163	Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thrombosis and Haemostasis, 2014, 112, .	3.4	0
164	Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin. Blood, 2014, 124, 1462-1462.	1.4	0
165	BehÃ§etâ€™s disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity. Orphanet Journal of Rare Diseases, 2013, 8, 81.	2.7	20
166	Joint aspiration of acute tense knee haemarthroses in adult haemophilia A patients. Thrombosis Research, 2013, 132, 778-779.	1.7	14
167	Rotational thromboelastometry (ROTEM) in BehÃ§et's disease. Clinical Rheumatology, 2013, 32, 1691-1691.	2.2	0
168	Radiosynovectomy. Blood Coagulation and Fibrinolysis, 2013, 24, 465-470.	1.0	30
169	Effective prophylaxis with rFVIIa in young haemophiliacs with inhibitors using a schedule similar to FVIII prophylaxis in non-inhibitor patients. Health, 2013, 05, 1151-1157.	0.3	1
170	Femur fracture in a woman with severe factor X deficiency - an experience using factor X concentrate in surgery. Haemophilia, 2013, 19, e369-e370.	2.1	5
171	Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia, 2013, 19, 481-486.	2.1	16
172	Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Haemophilia, 2013, 19, 841-846.	2.1	11
173	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	1.4	188
174	Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. Thrombosis and Haemostasis, 2013, 109, 909-919.	3.4	13
175	Procoagulant Status In Patients With Immune Thrombocytopenia. Blood, 2013, 122, 3528-3528.	1.4	1
176	The Pharmacokinetics Of Turoctocog Alfa Are Consistent Over Different Concentrations and Production Lots. Blood, 2013, 122, 4783-4783.	1.4	1
177	Effects Of Thrombopoietin Receptor Agonists On APRIL Plasma Levels In Patients With Immune Thrombocytopenia. Blood, 2013, 122, 1083-1083.	1.4	0
178	Consecutive radiosynovectomy procedures at 6-monthly intervals behave independently in haemophilic synovitis. Blood Transfusion, 2013, 11, 254-9.	0.4	17
179	An uncommon cause of elbow synovitis in an adult haemophilia patient. Blood Coagulation and Fibrinolysis, 2012, 23, 459-460.	1.0	0
180	Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in BehÃ§et disease patients. Thrombosis and Haemostasis, 2012, 107, 88-98.	3.4	25

#	Article	IF	Citations
181	PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thrombosis Research, 2012, 130, 864-870.	1.7	44
182	Management of delivery with FVIII/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodies. Thrombosis and Haemostasis, 2012, 108, 796-798.	3.4	6
183	Late avascular necrosis of the femoral head (anfh) after the percutaneous fixation of a nonâ€displaced fracture of the femoral neck in a haemophilic patient with inhibitors: a nonâ€reported association. Haemophilia, 2012, 18, e4-5.	2.1	2
184	Liver transplantation in Spanish haemophiliacs. Haemophilia, 2012, 18, e15-6.	2.1	2
185	Pharmacokinetic properties of two different recombinant activated factor VII formulations. Haemophilia, 2012, 18, 431-436.	2.1	6
186	Management of bleeding disorders in adults. Haemophilia, 2012, 18, 24-36.	2.1	8
187	Is onâ€demand treatment effective in patients with severe haemophilia?. Haemophilia, 2012, 18, 738-742.	2.1	15
188	Iatrogenic fracture of the proximal tibia as a complication of knee manipulation under anaesthesia in a haemophilia patient with an ipsilateral stiff knee secondary to a supracondylar nonâ€union of the femur. Haemophilia, 2012, 18, e354-6.	2.1	2
189	A complex case of infected total knee arthroplasty in a haemophilic patient with inhibitor. Haemophilia, 2012, 18, e357-9.	2.1	0
190	F8 gene dosage defects in atypical patients with severe haemophilia A. Haemophilia, 2012, 18, 708-713.	2.1	6
191	Optimizing joint function: new knowledge and novel tools and treatments. Haemophilia, 2012, 18, 17-26.	2.1	6
192	Efficacy of factor IX <scp>G</scp>rifols^{Â®} in surgery: experience of an international multicentre retrospective study. Haemophilia, 2012, 18, e372-3.	2.1	2
193	Treatment of Primary Immune Thrombocytopenia with Thrombopoietin Receptor Agonists: Effect On Platelet Function and Plasma Thrombin Generation. Blood, 2012, 120, 1089-1089.	1.4	0
194	Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center. Blood, 2012, 120, 4658-4658.	1.4	0
195	Microparticle-Associated Thrombogenic Mechanism Might Compensate Bleeding Tendency in Patients with Myelodysplastic Syndromes.. Blood, 2012, 120, 2821-2821.	1.4	0
196	Prophylaxis therapy in haemophilia A: current situation in Spain. Haemophilia, 2011, 17, 75-80.	2.1	14
197	Focusing on haemophilia B: prophylaxis in Spanish patients. Haemophilia, 2011, 17, 542-543.	2.1	6
198	When should prophylaxis therapy in inhibitor patients be considered?. Haemophilia, 2011, 17, e849-57.	2.1	26

#	Article	IF	Citations
199	Infection after total knee arthroplasty in haemophilic arthropathy with special emphasis on late infection. Haemophilia, 2011, 17, e831-2.	2.1	23
200	What patient, joint and isotope characteristics influence the response to radiosynovectomy in patients with haemophilia?. Haemophilia, 2011, 17, no-no.	2.1	41
201	An uncommon cause of knee haemarthrosis in an adult haemophilia patient suffering from longâ€term paraplegia. Haemophilia, 2011, 17, e845-6.	2.1	0
202	Joint protection in haemophilia. Haemophilia, 2011, 17, 1-23.	2.1	107
203	Radiosynovectomy in hemophilia: quantification of its effectiveness through the assessment of 10 articular parameters. Journal of Thrombosis and Haemostasis, 2011, 9, 928-935.	3.8	66
204	Radiosynovectomy in patients with chronic haemophilic synovitis: when is more than one injection necessary?. European Journal of Haematology, 2011, 86, 430-435.	2.2	30
205	Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia, 2010, 16, 84-88.	2.1	28
206	Review: Factor XI Deficiency: Review and Management in Pregnant Women. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 209-213.	1.7	14
207	Improving Type 1 Diabetes After Treatment of Immune Thrombocytopenia With Rituximab: Killing Two Birds With One Stone. Diabetes Care, 2010, 33, e122-e122.	8.6	5
208	Clinical and genetic findings in five female patients with haemophilia A: Identification of a novel missense mutation, p.Phe2127Ser. Thrombosis and Haemostasis, 2010, 104, 718-723.	3.4	15
209	Possible role for cellular FXIII in monocyte-derived dendritic cell motility. European Journal of Cell Biology, 2009, 88, 423-431.	3.6	22
210	Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia, 2009, 15, 203-209.	2.1	55
211	Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia, 2009, 15, 983-989.	2.1	35
212	Haemophilia in Spain. Haemophilia, 2009, 15, 665-675.	2.1	49
213	The role of selective angiographic embolization of the musculoâ€skeletal system in haemophilia. Haemophilia, 2009, 15, 864-868.	2.1	23
214	New insights into the expression and role of platelet factorÂXIIIâ€A. Journal of Thrombosis and Haemostasis, 2009, 7, 1184-1191.	3.8	24
215	Acquired von Willebrand syndrome. Haemophilia, 2008, 14, 856-858.	2.1	2
216	Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi^{Â®} a highly purified, doubly inactivated FVIII/VWF concentrate. Haemophilia, 2008, 14, 963-967.	2.1	23

#	Article	IF	Citations
217	Experiences in the prevention of arthropathy in haemophila patients with inhibitors. Haemophilia, 2008, 14, 28-35.	2.1	12
218	Orthopaedic surgery in haemophilia patients with inhibitors as the last resort. Haemophilia, 2008, 14, 56-67.	2.1	97
219	Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?. Haemophilia, 2008, 14, 68-81.	2.1	49
220	Controversies and Challenges in Elective Orthopedic Surgery in Patients With Hemophilia and Inhibitors. Seminars in Hematology, 2008, 45, S64-S67.	3.4	27
221	Management of the Delivery in Pregnant Women with Severe Factor XI Deficiency. Acta Haematologica, 2008, 119, 154-155.	1.4	3
222	â€œPrimary prophylaxisâ€•with rFVIIa in a patient with severe haemophilia a and inhibitor. Blood Coagulation and Fibrinolysis, 2008, 19, 719-720.	1.0	16
223	Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia, 2007, 13, 613-619.	2.1	38
224	Haemoperitoneum in a female patient with haemophilia A caused by a ruptured ovarian follicle. Haemophilia, 2007, 13, 770-771.	2.1	4
225	Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Annals of Hematology, 2006, 85, 400-406.	1.8	87
226	Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia, 2005, 11, 79-83.	2.1	71
227	Psychometric field study of the new haemophilia quality of life questionnaire for adults: The 'Hemofilia-QoL'. Haemophilia, 2005, 11, 603-610.	2.1	50
228	Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia, 2004, 10, 30-40.	2.1	68
229	Acquired Haemophilia: Review and Metaâ€Analysis Focused on Therapy and Prognostic Factors. British Journal of Haematology, 2003, 121, 21-35.	2.5	400
230	Analysis of the causes of immediate unanticipated bleeding after pediatric adenotonsillectomy. International Journal of Pediatric Otorhinolaryngology, 2003, 67, 341-344.	1.0	31
231	Otolaryngologic Surgery in Children With von Willebrand Disease. JAMA Otolaryngology, 2002, 128, 1365.	1.2	41
232	Successful thyroidectomy in a patient with Hermanskyâ€“Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagulation and Fibrinolysis, 2002, 13, 551-553.	1.0	26
233	Induction of a Hypercoagulability State and Endothelial Cell Activation by Granulocyte Colony-Stimulating Factor in Peripheral Blood Stem Cell Donors. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 675-681.	1.8	37
234	Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects. European Journal of Haematology, 2002, 69, 158-164.	2.2	22

#	Article	IF	Citations
235	The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents. Haemophilia, 2002, 8, 189-193.	2.1	23
236	Yttrium-90 synoviorthesis for chronic haemophilic synovitis: Madrid experience. Haemophilia, 2001, 7, 34-35.	2.1	49
237	Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia, 2001, 7, 551-556.	2.1	41
238	Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia, 2000, 6, 588-590.	2.1	48
239	Hematopoietic cell transplantation using plasma and DMSO without HES, with non-programmed freezing by immersion in a methanol bath: results in 213 cases. Bone Marrow Transplantation, 1998, 21, 511-517.	2.4	22
240	Posttransplant CD30 (Ki-1)â€“Positive Anaplastic Large Cell Lymphoma. Acta Cytologica, 1997, 41, 1519-1524.	1.3	40
241	Haemophilia A and chronic hepatopathy caused by extrahepatic biliary atresia: two congenital diseases cured by orthotopic liver transplantation. Haemophilia, 1997, 3, 145-148.	2.1	1
242	Osteonecrosis of the Femoral Head. , 0, , 153-158.		2
243	Plasmaâ€derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study. Haemophilia, 0, , .	2.1	2